Vera Therapeutics Newsroom

Scotiabank Initiates Vera Therapeutics at Sector Outperform

MT NewswiresOct 16 20:23

Vera Therapeutics (NASDAQ:VERA) Has Debt But No Earnings; Should You Worry?

Simply Wall StOct 7 23:45

TD Cowen Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $60

Futu NewsOct 7 20:31 · Ratings

Vera Therapeutics (VERA) Gets a Buy From TD Cowen

TipRanksOct 7 19:35 · Ratings

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswireOct 5 04:05

Jefferies Initiates Vera Therapeutics(VERA.US) With Buy Rating, Announces Target Price $53

Futu NewsOct 3 20:31 · Ratings

Evercore Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $50

Futu NewsOct 3 20:31 · Ratings

LifeSci Capital Maintains Vera Therapeutics(VERA.US) With Buy Rating, Raises Target Price to $70

Futu NewsOct 3 03:31 · Ratings

Vera Therapeutics' Atacicept: Promising Clinical Data and Strategic Expansion Fuel Buy Rating

TipRanksOct 3 03:05 · Ratings

Vera to Expand Atacicept Program Into Broader IgAN Population

Seeking AlphaOct 2 22:26

Vera Therapeutics Expands Development of Kidney Disease Drug Pipeline

MT NewswiresOct 2 19:08

Express News | Vera Therapeutics Inc - Multiple Regulatory and Clinical Milestones Expected Over Next 18 Months

BreakingsOct 2 18:30

Express News | Vera Therapeutics Announces Expanded Atacicept Development Program in Multiple Autoimmune Kidney Diseases

BreakingsOct 2 18:30

Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024

GlobeNewswireOct 2 18:30

Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases

GlobeNewswireOct 2 18:30

Express News | Vera Therapeutics Announces Late-Breaking Oral Presentation of Origin Phase 2B Long-Term Results at the American Society of Nephrology Kidney Week 2024

BreakingsOct 2 18:30

Cantor Fitzgerald Reiterates Overweight on Vera Therapeutics, Maintains $107 Price Target

BenzingaOct 1 20:16 · Ratings

Is Vera Therapeutics Inc. (VERA) the Best Performing Small-Cap Stock in 2024?

Yahoo FinanceSep 27 03:31

Cantor Fitzgerald Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $107

Cantor Fitzgerald analyst Pete Stavropoulos maintains $Vera Therapeutics(VERA.US)$ with a buy rating, and maintains the target price at $107.According to TipRanks data, the analyst has a success

Futu NewsSep 23 20:31 · Ratings

Vera Therapeutics Director Sells Over $696k in Company Stock

InvestingSep 21 04:50